Effect of DS-8500a, a Novel G Protein-Coupled Receptor 119 Agonist, on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects

ConclusionsMultiple doses of DS-8500a increased exposure to rosuvastatin and atorvastatin. This short-term study suggests that the impact of DS-8500a coadministration on atorvastatin exposure is limited and may not be clinically relevant. Nevertheless, caution may be necessary when patients are coadministered rosuvastatin with DS-8500a.ClinicalTrials.gov identifierNCT03699774.Japan Pharmaceutical Information Center identifierJapicCTI-152878.

http://link.springer.com/10.1007/s40261-019-00825-1

Source: Clinical Drug Investigation - July 17, 2019 Category: Drugs & Pharmacology Source Type: research